GSK has announced its largest U.S. manufacturing investment to date. The up to $800 million investment will bring state-of-the-art drug substance manufacturing and additional drug product manufacturing capabilities to the company’s site in Marietta, Pennsylvania, along with over 200 new jobs.
The new multi-purpose facility will be capable of manufacturing sterile liquid vaccines and medicines for which there is ever-increasing demand. This facility will also house a state-of-the-art R&D pilot plant to manufacture medicines for clinical trials.
Additionally, GSK will establish a new vaccines drug substance facility at the site, dedicated to manufacturing products based on the company’s novel MAPS technology, subsequent to future regulatory submissions and approvals. This expansion will double the size and capacity of the Marietta site.
Regis Simard, President Global Supply Chain, GSK, said: “This landmark investment will establish Marietta as an innovation and manufacturing hub capable of delivering next generation medicines and vaccines to people around the world. We’re grateful for the support of local and state officials, who made this project possible, and we are excited to expand upon the important work already underway at the Marietta site.”
Advancing GSK’s commitment to sustainability, the new drug product building at the Marietta site will be certified LEED Silver and will incorporate the latest technologies for solar panels, electric heat generation, and water and energy reclamation. Both facilities will feature smart utility and electrical system monitoring and controls, digital twins for continuous process optimization, robotics for material handling, and predictive maintenance and digital scheduling enabled by artificial intelligence.
Construction of the new facilities is expected to start by the end of this year. The drug substance facility is anticipated to be operational by the end of 2027, with the drug product facility following by the end of 2028.
Since 2017, GSK has invested close to $1.3 billion in U.S. manufacturing capabilities.
